126 related articles for article (PubMed ID: 38670552)
1. HPN328, a Trispecific T Cell-activating Protein Construct Targeting DLL3-Expressing Solid Tumors.
Molloy ME; Aaron WH; Barath M; Bush MC; Callihan EC; Carlin K; Cremin M; Evans T; Gamez Guerrero M; Hemmati G; Hundal AS; Lao L; Laurie P; Lemon BD; Lin SJ; O'Rear J; Patnaik P; Sotelo Rocha S; Santiago L; Strobel KL; Valenzuela LB; Wu CH; Yu S; Yu TZ; Anand BS; Law CL; Sun LL; Wesche H; Austin RJ
Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38670552
[TBL] [Abstract][Full Text] [Related]
2. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.
Giffin MJ; Cooke K; Lobenhofer EK; Estrada J; Zhan J; Deegen P; Thomas M; Murawsky CM; Werner J; Liu S; Lee F; Homann O; Friedrich M; Pearson JT; Raum T; Yang Y; Caenepeel S; Stevens J; Beltran PJ; Canon J; Coxon A; Bailis JM; Hughes PE
Clin Cancer Res; 2021 Mar; 27(5):1526-1537. PubMed ID: 33203642
[TBL] [Abstract][Full Text] [Related]
3. A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.
Hipp S; Voynov V; Drobits-Handl B; Giragossian C; Trapani F; Nixon AE; Scheer JM; Adam PJ
Clin Cancer Res; 2020 Oct; 26(19):5258-5268. PubMed ID: 32554516
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
Rudin CM; Reck M; Johnson ML; Blackhall F; Hann CL; Yang JC; Bailis JM; Bebb G; Goldrick A; Umejiego J; Paz-Ares L
J Hematol Oncol; 2023 Jun; 16(1):66. PubMed ID: 37355629
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer.
Zhang Y; Tacheva-Grigorova SK; Sutton J; Melton Z; Mak YSL; Lay C; Smith BA; Sai T; Van Blarcom T; Sasu BJ; Panowski SH
Clin Cancer Res; 2023 Mar; 29(5):971-985. PubMed ID: 36692420
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors.
Molloy ME; Austin RJ; Lemon BD; Aaron WH; Ganti V; Jones A; Jones SD; Strobel KL; Patnaik P; Sexton K; Tatalick L; Yu TZ; Baeuerle PA; Law CL; Wesche H
Clin Cancer Res; 2021 Mar; 27(5):1452-1462. PubMed ID: 33262134
[TBL] [Abstract][Full Text] [Related]
7. Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.
Mikami H; Feng S; Matsuda Y; Ishii S; Naoi S; Azuma Y; Nagano H; Asanuma K; Kayukawa Y; Tsunenari T; Kamikawaji S; Iwabuchi R; Shinozuka J; Yamazaki M; Kuroi H; Ho SSW; Gan SW; Chichili P; Pang CL; Yeo CY; Shimizu S; Hironiwa N; Kinoshita Y; Shimizu Y; Sakamoto A; Muraoka M; Takahashi N; Kawa T; Shiraiwa H; Mimoto F; Kashima K; Kamata-Sakurai M; Ishikawa S; Aburatani H; Kitazawa T; Igawa T
Cancer Immunol Res; 2024 Apr; ():OF1-OF12. PubMed ID: 38563577
[TBL] [Abstract][Full Text] [Related]
8. Engineering CD3/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small cell lung cancer.
Mikami H; Feng S; Matsuda Y; Ishii S; Naoi S; Azuma Y; Nagano H; Asanuma K; Kayukawa Y; Tsunenari T; Kamikawaji S; Iwabuchi R; Shinozuka J; Yamazaki M; Kuroi H; Ho SSW; Gan SW; Chichili P; Pang CL; Yeo CY; Shimizu S; Hironiwa N; Kinoshita Y; Shimizu Y; Sakamoto A; Muraoka M; Takahashi N; Kawa T; Shiraiwa H; Mimoto F; Kashima K; Kamata-Sakurai M; Ishikawa S; Aburatani H; Kitazawa T; Igawa T
Cancer Immunol Res; 2024 Mar; ():. PubMed ID: 38558120
[TBL] [Abstract][Full Text] [Related]
9. TREM1/DAP12 based novel multiple chain CAR-T cells targeting DLL3 show robust anti-tumour efficacy for small cell lung cancer.
Nie F; Chen Y; Hu Y; Huang P; Shi X; Cai J; Qiu M; Wang E; Lu K; Sun M
Immunology; 2024 Mar; ():. PubMed ID: 38469682
[TBL] [Abstract][Full Text] [Related]
10. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models.
Jaspers JE; Khan JF; Godfrey WD; Lopez AV; Ciampricotti M; Rudin CM; Brentjens RJ
J Clin Invest; 2023 May; 133(9):. PubMed ID: 36951942
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.
Wermke M; Felip E; Gambardella V; Kuboki Y; Morgensztern D; Hamed ZO; Liu M; Studeny M; Owonikoko TK
Future Oncol; 2022 Aug; 18(24):2639-2649. PubMed ID: 35815644
[TBL] [Abstract][Full Text] [Related]
12. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
[TBL] [Abstract][Full Text] [Related]
13. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer.
Isobe Y; Sato K; Nishinaga Y; Takahashi K; Taki S; Yasui H; Shimizu M; Endo R; Koike C; Kuramoto N; Yukawa H; Nakamura S; Fukui T; Kawaguchi K; Chen-Yoshikawa TF; Baba Y; Hasegawa Y
EBioMedicine; 2020 Feb; 52():102632. PubMed ID: 31981983
[TBL] [Abstract][Full Text] [Related]
14. First-in-human imaging with [
Tendler S; Dunphy MP; Agee M; O'Donoghue J; Aly RG; Choudhury NJ; Kesner A; Kirov A; Mauguen A; Baine MK; Schoder H; Weber WA; Rekhtman N; Lyashchenko SK; Bodei L; Morris MJ; Lewis JS; Rudin CM; Poirier JT
medRxiv; 2024 Jan; ():. PubMed ID: 38260492
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
Chou J; Egusa EA; Wang S; Badura ML; Lee F; Bidkar AP; Zhu J; Shenoy T; Trepka K; Robinson TM; Steri V; Huang J; Wang Y; Small EJ; Chan E; Stohr BA; Ashworth A; Delafontaine B; Rottey S; Cooke KS; Hashemi Sadraei N; Yu B; Salvati M; Bailis JM; Feng FY; Flavell RR; Aggarwal R
Cancer Res; 2023 Jan; 83(2):301-315. PubMed ID: 36351060
[TBL] [Abstract][Full Text] [Related]
16. Delta-like ligand 3 in small cell lung cancer: Potential mechanism and treatment progress.
Yang W; Wang W; Li Z; Wu J; Huang X; Li J; Zhang X; Ye X
Crit Rev Oncol Hematol; 2023 Nov; 191():104136. PubMed ID: 37716517
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Morgensztern D; Besse B; Greillier L; Santana-Davila R; Ready N; Hann CL; Glisson BS; Farago AF; Dowlati A; Rudin CM; Le Moulec S; Lally S; Yalamanchili S; Wolf J; Govindan R; Carbone DP
Clin Cancer Res; 2019 Dec; 25(23):6958-6966. PubMed ID: 31506387
[TBL] [Abstract][Full Text] [Related]
18. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
[TBL] [Abstract][Full Text] [Related]
19. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
Yao J; Bergsland E; Aggarwal R; Aparicio A; Beltran H; Crabtree JS; Hann CL; Ibrahim T; Byers LA; Sasano H; Umejiego J; Pavel M
Oncologist; 2022 Nov; 27(11):940-951. PubMed ID: 35983951
[TBL] [Abstract][Full Text] [Related]
20. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
